Kirkland Represents Edding Group on its Proposed Merger and Reverse Takeover with Genor Biopharma
Kirkland & Ellis is representing Edding Group Company Limited, an integrated biopharmaceutical company focusing on research, development and commercialization of promising therapeutics in areas with considerable demand in the PRC, in connection with a proposed merger and reverse takeover with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A that focuses on developing and commercializing oncology and immunology drugs. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company and the only announced reverse takeover case in Hong Kong recently.
The proposed merger is expected to bring complementary and synergetic effects to both Genor Biopharma and Edding Group, laying an important foundation for the sustainable development of the enlarged group post-merger closing.
The transaction is subject to customary closing conditions.
The Kirkland team included capital markets lawyer Mengyu Lu; corporate lawyers Joey Chau, Ashlee Wu, Leo Zhou, Chuanwen Wang and Rock Liu; and corporate registered foreign lawyer Sherry Fu.
